Mar
20
Lilly Launches Mounjaro Tirzepatide for Obesity and Type 2 Diabetes
Mumbai, March 20, 2025: Eli Lilly and Company (India) today announced the launch of Mounjaro® in single-dose vial presentation following the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone […]